Real-world cohort shows that elevated FeNO and blood eosinophils increase clinical remission likelihood in severe asthma, suggesting targeted treatment benefits.
In this real-world cohort of patients with severe eosinophilic asthma treated with biologics, concomitant baseline elevation of FeNO and blood eosinophils was associated with a higher likelihood of achieving clinical remission at 12 months.
No takes yet. Share an insight, caveat, or question.
Pianigiani et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: